Type your tag names separated by a space and hit enter
Immunotherapy for advanced renal cancer
There's more to see -- the rest of this topic is available only to subscribers.
"Immunotherapy for Advanced Renal Cancer." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/456003/all/__________Immunotherapy_for_advanced_renal_cancer______.
Immunotherapy for advanced renal cancer. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/456003/all/__________Immunotherapy_for_advanced_renal_cancer______. Accessed September 26, 2023.
Immunotherapy for advanced renal cancer. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/456003/all/__________Immunotherapy_for_advanced_renal_cancer______
Immunotherapy for Advanced Renal Cancer [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 September 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/456003/all/__________Immunotherapy_for_advanced_renal_cancer______.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Immunotherapy for advanced renal cancer
ID - 456003
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/456003/all/__________Immunotherapy_for_advanced_renal_cancer______
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
Try the app for free!
1. Download the Evidence Central app by Unbound Medicine
2. Select Try/Buy and follow instructions to begin your free 30-day trial
You can cancel anytime within the 30-day trial, or continue using Evidence Central to begin a 1-year subscription ($39.95)
Your free 1 year of online access expired .
Want to regain access to Evidence Central?
Log in to Evidence Central
If you need further assistance, please contact Support.